$TPST

Tempest Therapeutics receives Nasdaq notice for listing deficiencies

Tempest Therapeutics (NASDAQ:TPST) has received a notice from Nasdaq regarding listing deficiencies. The company is not in compliance with Nasdaq's minimum stockholders’ equity requirement and also faces issues with independent directors and board committees due to recent resignations. Tempest Therapeutics has 45 days to submit a plan to regain compliance, but these notifications do not immediately affect the trading of its common stock.

Original reporting
Investing.com · Investing.com
Published May 23, 2026, 10:39 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 23, 2026, 11:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Tempest Therapeutics receives Nasdaq notice for listing deficiencies — source image
Decision brief

The 30-second read

$TPSTBearishMed
01

Why it matters

The non-compliance could lead to delisting if not addressed, causing stock price volatility and potential loss of investor confidence.

02

Market read

High relevance for current shareholders and potential investors due to imminent compliance deadline.

03

What to watch

The company's underlying clinical pipeline and financial health may mitigate some concerns if they demonstrate strong fundamentals.

Timing: Immediate, as the company has 45 days to submit a plan to regain compliance.

Background

Tempest Therapeutics is facing regulatory compliance issues with Nasdaq, primarily due to financial and governance concerns.

Company-level read

Ticker impact

$TPSTBearishMedium confidence
Context

High relevance due to direct impact on company fundamentals and stock price.

Expected impact

Potential short-term decline of 10-15% if the company fails to address the deficiencies promptly.

Evidence & confidence

The company's non-compliance with Nasdaq requirements could lead to investor concerns about financial stability and corporate governance, impacting stock performance.

Market effects

Potential negative sentiment in the biotech/life sciences sector due to regulatory and compliance concerns.

Limited, as the news pertains to a U.S.-listed company and does not affect broader regional markets.

Negligible; specific to company and sector.

Counterpoint

If the company successfully submits a credible plan within the 45-day window, positive investor sentiment could recover, leading to a rebound.

Key entities

  • Tempest Therapeutics

    A biotech company focused on developing targeted therapies.

Related articles

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.

$LMTMed

Pentagon pushes military contractors to accelerate production amid shortages after war on Iran

The Pentagon ordered US defense contractors to submit within 21 days plans to accelerate production of missiles and interceptors amid shortages after the first month of strikes against Iran. It cited depleted Patriot and THAAD inventories and said framework agreements with Lockheed Martin and Northrop Grumman target PAC-3 and THAAD output. Lockheed Martin received a contract up to $58.6B to triple PAC-3 production by 2030.